Thomas Richard Belliotti - Saline MI Justin Stephen Bryans - Balsham, GB Ihoezo Victor Ekhato - West Chester PA Augustine Tobi Osuma - Ann Arbor MI Robert Michael Schelkun - Ypsilanti MI Jacob Bradley Schwarz - Ann Arbor MI Andrew John Thorpe - Ann Arbor MI Lawrence David Wise - Ann Arbor MI David Juergen Wustrow - Ann Arbor MI
The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.
Bicyclic Cyclohexylamines And Their Use As Nmda Receptor Antagonists
Russell Joseph Deorazio - Schenectady NY Sham Shridhar Nikam - Ann Arbor MI Ian Leslie Scott - Delanson NY Brian Alan Sherer - Clifton Park NY Lawrence David Wise - Ann Arbor MI
Described are heterocycle-substituted cyclohexylamines of formula (I), and their pharmaceutically acceptable salts thereof. The compounds of the formula (I) are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinsons disease,.
Cyclohexylamine Derivatives As Subtype Selective Nmda Receptor Antagonists
Russell Joseph Deorazio - Schnectady NY Sham Shridhar Nikam - Ann Arbor MI Ian Leslie Scott - Delanson NY Brian Alan Sherer - Clifton Park NY Lawrence David Wise - Ann Arbor MI
Described are cyclobexylamine derivatives of Formula I, Formula II, or Formula III and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinsons disease. The substituents are described in the specification.
Bicyclic Cyclohexylamines And Their Use As Nmda Receptor Antagonists
Sham Shridhar Nikam - Ann Arbor MI Ian Leslie Scott - Delanson NY Brian Alan Sherer - Ballston Spa NY Lawrence David Wise - Ann Arbor MI
Assignee:
Warner-Lambert Company - Morris Plains NJ
International Classification:
A61K 31423
US Classification:
514375, 548221
Abstract:
Described are bicycle-substituted cyclohexylamines of Formula I and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinsons disease. The substituents are defined in the specification.
Cyclohexylamine Derivative As Subtype Selective Nmda Receptor Antagonists
Russell Joseph Deorazio - Schenectady NY, US Sham Shridhar Nikam - Ann Arbor MI, US Ian Leslie Scott - Delanson NY, US Brian Alan Sherer - Ballston Spa NY, US Lawrence David Wise - Ann Arbor MI, US
Described are compounds of Formula I and Formula II and their pharmaceutically acceptable salts. The compounds of Formulas I and II are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease.
Thomas Belliotti - Saline MI, US Justin Bryans - Balsham, GB Ihoezo Ekhato - West Chester PA, US Augustine Osuma - Canton MI, US Robert Schelkun - Milan MI, US Jacob Schwarz - Ann Arbor MI, US Andrew Thorpe - Ann Arbor MI, US Lawrence Wise - Ann Arbor MI, US David Wustrow - Ann Arbor MI, US
International Classification:
A61K031/195
US Classification:
514/561000, 514/567000
Abstract:
The instant invention is a series of novel mono- and disubstituted 3-propyl gamma aminobutyric acids of Formula I The compounds are useful as therapeutic agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, arthritis, sleep disorders, IBS, and gastric damage. Methods of preparing the compounds and useful intermediates are also part of the invention.
Horace A. DeWald - Ann Arbor MI Lawrence D. Wise - Ann Arbor MI
Assignee:
Warner-Lambert Company - Morris Plains NJ
International Classification:
A61K 31535 C07D49804
US Classification:
5142298
Abstract:
trans-Benzopyran-4,3b-1,4-oxazines are described as well as methods of preparation. The compounds are presynaptic dopamine agonists and may be used in pharmaceutical composition form for treating psychoses, e. g. , schizophrenia.